Evidence map›Paper›PMID 34041621›Full record

ArticleBreast cancer research and treatment2021

Combinatorial targeting of microRNA-26b and microRNA-101 exerts a synergistic inhibition on cyclooxygenase-2 in brain metastatic triple-negative breast cancer cells.

Rania Harati, Aloïse Mabondzo, Abdelaziz Tlili, Ghalia Khoder, Mona Mahfood, Rifat Hamoudi

Open access · greenAbstract read
PubMed Publisher
In one paragraph

Article in Breast cancer research and treatment, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed, 1 pooled it
2.1field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

15 citing papers in PubMed, 1 synthesis or guideline pooled it, 30 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Review
  4. Review
  5. Article
  6. Article
  7. Review
  8. Molecular Heterogeneity of the Brain Endothelium.Current issues in molecular biology · 2023
    Article
  9. Review
  10. Review
  11. Review
  12. Article
  13. Review
  14. Article
  15. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 3 countries.

Rania HaratiDepartment of Pharmacy Practice and Pharmacotherapeutics, College of Pharmacy, University of Sharjah, 27272, Sharjah, United Arab Emirates. rharati@sharjah.ac.ae.ORCID http://orcid.org/0000-0001-6672-2944
Aloïse MabondzoDepartment of Medicines and Healthcare Technologies, The French Alternative Energies and Atomic Energy Commission, Paris-Saclay University, 91191, Gif-sur-Yvette, France.
Abdelaziz TliliDepartment of Applied Biology, College of Sciences, University of Sharjah, 27272, Sharjah, United Arab Emirates.ORCID http://orcid.org/0000-0002-8039-3013
Ghalia KhoderSharjah Institute for Medical Research, University of Sharjah, 27272, Sharjah, United Arab Emirates.
Mona MahfoodDepartment of Applied Biology, College of Sciences, University of Sharjah, 27272, Sharjah, United Arab Emirates.
Rifat HamoudiSharjah Institute for Medical Research, University of Sharjah, 27272, Sharjah, United Arab Emirates.ORCID http://orcid.org/0000-0001-6630-4814
University of Sharjah · AECommissariat à l'Énergie Atomique et aux Énergies Alternatives · FR

Funding

Al Jalila Foundation AJF201741Terry Fox Foundation I1032
6 · The paper itself

Abstract

purposeExtravasation of triple-negative (TN) metastatic breast cancer (BC) cells through the brain endothelium (BE) is a critical step in brain metastasis (BM). During extravasation, metastatic cells induce alteration in the inter-endothelial junctions and transmigrate through the endothelial barrier. Transmigration of metastatic cells is mediated by the upregulation of cyclooxygenase-2 (COX-2) that induces matrix metalloproteinase-1 (MMP-1) capable of degrading inter-endothelial junctional proteins. Despite their important role in BM, the molecular mechanisms upregulating COX-2 and MMP-1 in TNBC cells remain poorly understood. In this study, we unraveled a synergistic effect of a pair of micro-RNAs (miR-26b-5p and miR-101-3p) on COX-2 expression and the brain transmigration ability of BC cells.

methodsUsing a gain-and-loss of function approach, we modulated levels of miR-26b-5p and miR-101-3p in two TNBC cell lines (the parental MDA-MB-231 and its brain metastatic variant MDA-MB-231-BrM2), and examined the resultant effect on COX-2/MMP-1 expression and the transmigration of cancer cells through the BE.

resultsWe observed that the dual inhibition of miR-26b-5p and miR-101-3p in BC cells results in higher increase of COX-2/MMP-1 expression and a higher trans-endothelial migration compared to either micro-RNA alone. The dual restoration of both micro-RNAs exerted a synergistic inhibition on COX-2/MMP-1 by targeting COX-2 and potentiated the suppression of trans-endothelial migration compared to single micro-RNA.

conclusionThese findings provide new insights on a synergism between miR-26-5p and miR-101-3p in regulating COX-2 in metastatic TNBC cells and shed light on miR-26-5p and miR-101-3p as prognostic and therapeutic targets that can be exploited to predict or prevent BM.

Indexed as

Cyclooxygenase 2MicroRNAsTriple Negative Breast NeoplasmsBrainCell Line, TumorCell MovementGene Expression Regulation, NeoplasticHumansCyclooxygenase 2MicroRNAsMIRN101 microRNA, humanMIRN26 microRNA, humanPTGS2 protein, humanBlood–brain barrierBrain metastasisBreast cancerCOX-2miR-101miR-26b

Identifiers

PMID34041621
OpenAlexW3165029584

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.